NYSEMKT:IGC IGC Pharma (IGC) Stock Price, News & Analysis $0.34 +0.01 (+3.34%) Closing price 03/14/2025 03:58 PM EasternExtended Trading$0.34 0.00 (-0.30%) As of 03/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC Filings About IGC Pharma Stock (NYSEMKT:IGC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IGC Pharma alerts:Sign Up Key Stats Today's Range$0.32▼$0.3450-Day Range$0.27▼$0.3652-Week Range N/AVolume214,616 shsAverage Volume383,424 shsMarket Capitalization$26.85 millionP/E RatioN/ADividend YieldN/APrice Target$3.88Consensus RatingBuy Company OverviewIGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Read More… Remove Ads IGC Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreIGC MarketRank™: IGC Pharma scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIGC Pharma has only been the subject of 2 research reports in the past 90 days.Read more about IGC Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for IGC Pharma are expected to decrease in the coming year, from ($0.11) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGC Pharma is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGC Pharma is -3.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGC Pharma has a P/B Ratio of 4.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for IGC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIGC Pharma does not currently pay a dividend.Dividend GrowthIGC Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for IGC. News and Social Media1.1 / 5News SentimentN/A Search Interest3 people have searched for IGC on MarketBeat in the last 30 days. MarketBeat Follows3 people have added IGC Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, IGC Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders31.48% of the stock of IGC Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.87% of the stock of IGC Pharma is held by institutions.Read more about IGC Pharma's insider trading history. Receive IGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGC Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IGC Stock News HeadlinesIGC Pharma's (IGC) Buy Rating Reiterated at Alliance Global PartnersMarch 9, 2025 | americanbankingnews.comIGC Pharma, Inc. (IGC) Advances AI Model to Enhance Alzheimer’s DiagnosisMarch 6, 2025 | insidermonkey.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.March 16, 2025 | Altimetry (Ad)IGC Pharma, Inc.: IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia DetectionMarch 4, 2025 | finanznachrichten.deIGC Pharma develops AI-driven model to improve diagnosis of Alzheimer’sMarch 4, 2025 | markets.businessinsider.comIGC Pharma reports Q3 EPS (2c) vs. (9c) last yearFebruary 20, 2025 | markets.businessinsider.comIGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’February 20, 2025 | markets.businessinsider.comIGC Pharma, Inc.: IGC Pharma Reports Third Quarter Fiscal 2025 ResultsFebruary 18, 2025 | finanznachrichten.deSee More Headlines IGC Stock Analysis - Frequently Asked Questions How have IGC shares performed this year? IGC Pharma's stock was trading at $0.3360 at the beginning of 2025. Since then, IGC shares have increased by 0.3% and is now trading at $0.3370. View the best growth stocks for 2025 here. How were IGC Pharma's earnings last quarter? IGC Pharma, Inc. (NYSEMKT:IGC) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. The firm had revenue of $0.41 million for the quarter, compared to analysts' expectations of $0.29 million. IGC Pharma had a negative trailing twelve-month return on equity of 122.44% and a negative net margin of 714.16%. Who are IGC Pharma's major shareholders? IGC Pharma's top institutional shareholders include Geode Capital Management LLC (0.86%), Squarepoint Ops LLC (0.16%), Northern Trust Corp (0.15%) and Citadel Advisors LLC. View institutional ownership trends. How do I buy shares of IGC Pharma? Shares of IGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IGC Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGC Pharma investors own include Jiuzi (JZXN), Plug Power (PLUG), Avalon GloboCare (ALBT), Ainos (AIMD), Aethlon Medical (AEMD), Aditxt (ADTX) and Adial Pharmaceuticals (ADIL). Company Calendar Last Earnings11/12/2024Today3/16/2025Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEMKT SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEMKT:IGC CIK1326205 Webigcpharma.com Phone(301) 983-0998Fax240-465-0273Employees61Year FoundedN/APrice Target and Rating Average Stock Price Target$3.88 High Stock Price Target$4.25 Low Stock Price Target$3.50 Potential Upside/Downside+1,049.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,000,000.00 Net Margins-714.16% Pretax Margin-712.70% Return on Equity-122.44% Return on Assets-88.40% Debt Debt-to-Equity Ratio0.02 Current Ratio1.15 Quick Ratio0.98 Sales & Book Value Annual Sales$1.24 million Price / Sales21.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.08 per share Price / Book4.21Miscellaneous Outstanding Shares79,685,000Free Float54,600,000Market Cap$26.85 million OptionableN/A Beta1.21 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NYSEMKT:IGC) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredOur #1 Defense Stock for MarchChina just deepened its military alliance with America's enemies in the Middle East... By conducting joint ...Behind the Markets | SponsoredIs 2025 really the best time to get rich in American history?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGC Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGC Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.